Literature DB >> 32031423

The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis.

William Huynh1,2, Rebekah Ahmed1,3, Colin J Mahoney1, Chilan Nguyen1,4, Sicong Tu1,5, Jashelle Caga1, Patricia Loh1, Cindy S-Y Lin1, Matthew C Kiernan1,3.   

Abstract

Introduction: A spectrum of non-motor manifestations in amyotrophic lateral sclerosis (ALS) patients has been increasingly recognized, with cognitive and behavioral impairments the most prominent. Evidence suggests that ALS overlaps on a pathological, genetic, and clinical level with frontotemporal dementia (FTD), thereby suggesting a frontotemporal spectrum disorder (ALS-FTSD). Cognitive impairment has been reported in up to 75% of ALS patients, whilst the rate of behavioral dysfunction ranges up to 50%.Areas covered: The present review explores the current understanding of cognitive and behavioral changes in ALS with a particular emphasis on its implications on prognosis and survival.Expert commentary: Further longitudinal studies are needed to clarify the evolution of cognitive impairment in ALS and how this may ultimately influence survival. Improving understanding of cognitive changes has important implications toward the capacity of patients in making critical medical decisions. There is a need to develop a universally accepted and validated cognitive assessment tool to be administered in a multidisciplinary clinic that is efficient and sensitive, as well as being integrated into the design and analysis of future ALS drug trials. In addition, revision of the ALS diagnostic criteria is critically needed that should accommodate cognitive and behavioral symptoms in addition to motor manifestations.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; behavior; cognition; motor neuron disease; prognosis; survival

Year:  2020        PMID: 32031423     DOI: 10.1080/14737175.2020.1727740

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  5 in total

Review 1.  Cognitive and behavioral involvement in ALS has been known for more than a century.

Authors:  Stefano Zago; Lorenzo Lorusso; Edoardo N Aiello; Martino Ugolini; Barbara Poletti; Nicola Ticozzi; Vincenzo Silani
Journal:  Neurol Sci       Date:  2022-09-02       Impact factor: 3.830

Review 2.  Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders.

Authors:  Juan Miguel Godoy-Corchuelo; Luis C Fernández-Beltrán; Zeinab Ali; María J Gil-Moreno; Juan I López-Carbonero; Antonio Guerrero-Sola; Angélica Larrad-Sainz; Jorge Matias-Guiu; Jordi A Matias-Guiu; Thomas J Cunningham; Silvia Corrochano
Journal:  Biomedicines       Date:  2022-05-10

Review 3.  Improving clinical trial outcomes in amyotrophic lateral sclerosis.

Authors:  Matthew C Kiernan; Steve Vucic; Kevin Talbot; Christopher J McDermott; Orla Hardiman; Jeremy M Shefner; Ammar Al-Chalabi; William Huynh; Merit Cudkowicz; Paul Talman; Leonard H Van den Berg; Thanuja Dharmadasa; Paul Wicks; Claire Reilly; Martin R Turner
Journal:  Nat Rev Neurol       Date:  2020-12-18       Impact factor: 42.937

4.  Functional connectivity-based prediction of global cognition and motor function in riluzole-naive amyotrophic lateral sclerosis patients.

Authors:  Luqing Wei; Chris Baeken; Daihong Liu; Jiuquan Zhang; Guo-Rong Wu
Journal:  Netw Neurosci       Date:  2022-02-01

Review 5.  Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.

Authors:  Belgin Sever; Halilibrahim Ciftci; Hasan DeMirci; Hilal Sever; Firdevs Ocak; Burak Yulug; Hiroshi Tateishi; Takahisa Tateishi; Masami Otsuka; Mikako Fujita; Ayşe Nazlı Başak
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.